At a glance
ClinicalIndex Comparison Record- ✓HIV infection confirmed by at least one inpatient or ≥2 outpatient HIV-related codes 30-730 days apart
- ✓Age ≥18 years at first HIV-related code
- ✓Continuous enrollment in medical and pharmacy plans for ≥6 months after first HIV-related code
- ✕Prior PCV13 vaccination before first HIV-related code
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Assessment of 13-valent Pneumococcal Conjugate Vaccine Effectiveness Among People With HIV in the United States
In Brief
An observational study evaluating Vaccine Administration for HIV and 2 related conditions. Completed, enrolled 350,399 participants across 1 site.
Detailed Summary
The purpose of this study is to learn about how well a vaccine (Prevnar 13, PCV13) works in preventing disease in adults with HIV. The diseases studied are pneumonia. Mostly the ones caused by the bacteria - pneumococcus. This study also evaluates the type of pneumonia that is spread into the bloodstream. All participants in the study will be identified in health care databases. Adults with HIV will be identified by looking for a medical diagnosis that has confirmed HIV from the databases. Vaccination will be identified in the databases by looking for vaccine administration or for PCV13. Participants will be followed in the databases to see if they have one of the diseases mentioned above or not. The number of vaccinated participants with the diseases will be compared to the number participants without the vaccines but with the diseases. This will help to understand how well the vaccine worked.
Study Details
Timeline
Interventions
PCV13 administration